Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Q BioMed Inc welcomes autism language expert to advisory committee

Dr Helen Tager-Flusberg has provided the protocol for capturing the primary endpoint of the planned trial for QBM-001.
Q BioMed Inc welcomes autism language expert to advisory committee
The condition is one that affects very young (1 to 2yrs of age) children who are on the autistic spectrum

Shares in Q BioMed Inc (OTCMKTS:QBIO) advanced over 5% as it welcomed an autism language expert to its  advisory committee for its candidate  for non-verbal disorder in toddlers.

Dr Helen Tager-Flusberg has provided the protocol for capturing the primary endpoint of the planned trial for QBM-001.

"We are honoured to have Dr. Helen Tager-Flusberg join our advisory committee for QBM-001.

"She is a pioneer in her field, working with autism spectrum disorders to design speech and language assessment measures to capture their progress," said, Denis Corin, the chief executive of Q BioMed Inc.

Her newest assessment tool is called ELSA-T, which stands for 'expressive learning sample assessment for toddlers'.

Q BioMed is preparing to use ELSA-T to capture language development as the primary endpoint for when toddlers are treated with QBM-001 in the planned clinical trial in 2018.

Around 20,000 new cases of the disorder  are diagnosed in the USA each year and a similar amount in Europe.

The condition is one that affects very young (1 to 2yrs of age) children who are on the autistic spectrum.

The result is known as a ‘non-verbal disorder’ and is accompanied with developmental delay, where the toddlers either never learn to speak or lose the ability to speak.

Not all individuals who become nonverbal will benefit from QBM-001, the firm noted,  but testing from trained specialists and blood tests, coupled with genetic testing can identify a targeted population that will have a higher likelihood of responding to treatment.

Shares gained 5.63% to C$5.25.

View full QBIO profile View Profile

Q BioMed Inc Timeline

Related Articles

Harley Street sign
December 07 2017
The injection will bankroll the continuing technical development of the firm’s first LIGHT system and its installation at the Harley Street Proton Therapy Centre
picture of addict
November 15 2017
To build the UK's first £1bn, self-sustainable biotech is the aim for chief executive Clive Dix
1511901712_biotech_517925923.jpg
November 29 2017
The company has developed a "unique and superior pressure" cycling technology (PCT), says Zacks.

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use